Hosted by the Chengdu High-Tech Medical Association, the online event took place on April 12, 2025, with a special focus on dyslipidemia as a key metabolic risk factor and its pivotal role in the pathogenesis of the "three highs" comorbidities.

       In the era of precision medicine, the symposium conducted in-depth analysis of population-specific lipid metabolism characteristics, particularly emphasizing early screening and intervention strategies for special populations such as those with familial hypercholesterolemia. The conference innovatively proposed a lipidomics-based personalized risk assessment model and systematically examined the clinical potential and safety profiles of novel lipid-lowering therapies for patients with comorbidities. Experts also engaged in thorough discussions about the unique value of lipid management in diabetic patients with hypertension, sharing cutting-edge clinical evidence and updated guideline recommendations from both domestic and international sources. By establishing this multidisciplinary academic platform, the symposium has provided novel insights for improving China's dyslipidemia prevention and treatment system. Its emphasis on standardizing lipid screening and management protocols in primary care settings will significantly enhance comprehensive prevention and control of the "three highs" comorbidities, ultimately contributing to the Healthy China initiative.